Neuroleptic malignant syndrome and hydroxylase gene mutations

書誌事項

タイトル別名
  • no association with CYP2D6A or CYP2D6B

この論文をさがす

説明

To examine a possible association between debrisoquine 4-hydroxylase gene mutations and neuroleptic malignant syndrome, we assessed frequencies of wild type and A and B mutant alleles of the CYP2D6 gene in 24 patients with a history of neuroleptic malignant syndrome, 50 patients with neuroleptic-treated schizophrenia but no history of neuroleptic malignant syndrome, and 50 healthy controls. Allele frequencies did not differ significantly between these groups. Homozygotes for CYP2D6A and for CYP2D6B, which indicate a poor-metabolizer phenotype for the CYP2D6 substrate, were not detected among the neuroleptic malignant syndrome cases. This result indicates no excess of poor CYP2D6 metabolizers in neuroleptic malignant syndrome. The aetiology of neuroleptic malignant syndrome is not explainable in terms of CYP2D6 gene mutations.

収録刊行物

  • Psychiatric Genetics

    Psychiatric Genetics 7 127-130, 1997-01-01

    Ovid Technologies (Wolters Kluwer Health)

詳細情報 詳細情報について

問題の指摘

ページトップへ